- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Calidi Biotherapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.07. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 | 2 | GlobeNewswire (USA) | ||
| CALIDI BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 24.06. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic Summit | 1 | GlobeNewswire (USA) | ||
| 23.06. | Calidi Biotherapeutics appoints Corsee Sanders to board | 1 | Investing.com | ||
| 23.06. | Calidi Biotherapeutics beruft Corsee Sanders in den Verwaltungsrat | 1 | Investing.com Deutsch | ||
| 18.06. | Calidi Biotherapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 16.06. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study | 109 | GlobeNewswire (Europe) | SAN DIEGO, June 16, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) ("Calidi" or "the Company"), a biotechnology company pioneering the development of targeted genetic... ► Artikel lesen | |
| 05.06. | RedChip Companies, Inc.: Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on June 9 | 495 | ACCESS Newswire | ORLANDO, FL / ACCESS Newswire / June 5, 2026 / RedChip Companies will host an investor webinar with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) ("Calidi" or "the Company") on June 9, 2026, at... ► Artikel lesen | |
| 29.05. | Calidi Biotherapeutics, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 26.05. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Online Abstract Acceptances at the 2026 ASCO Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 23.05. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Provides Required NYSE American Disclosure | 223 | GlobeNewswire (Europe) | SAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) ("Calidi" or "the Company"), a biotechnology company pioneering the development of targeted genetic medicines... ► Artikel lesen | |
| 14.05. | Calidi BioTherapeutics GAAP EPS of -$0.43 | 1 | Seeking Alpha | ||
| 14.05. | Calidi Biotherapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.05. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights | 277 | GlobeNewswire (Europe) | Presented new data on CLD-401 at the AACR conference in San Diego, CA, detailing the profound immune changes in the tumor microenvironment induced by CLD-401; IND filing for CLD-401 expected by end... ► Artikel lesen | |
| 08.05. | Calidi Biotherapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 20.04. | Calidi presents cancer therapy data at AACR meeting | 3 | Investing.com | ||
| 20.04. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026 | 1 | GlobeNewswire (USA) | ||
| 14.04. | Calidi to present RedTail platform data at Iceland conference | 2 | Investing.com | ||
| 27.03. | Calidi Biotherapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 27.03. | Calidi Biotherapeutics, Inc. - 8-K, Current Report | - | SEC Filings |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 80,05 | -0,31 % | KI, Onkologie und Rüstung: TeamViewer, BioNTech & Antimony Resources - Ein Mix fürs Portfolio! | Erstellt und veröffentlicht im Auftrag von Antimony Resources Corp. Die Börse ist ein Ort der Extreme und wir blicken heute mit TeamViewer, BioNTech und Antimony Resources auf ein Trio, das aus 3 verschiedenen... ► Artikel lesen | |
| CLINUVEL | 6,190 | +1,04 % | CLINUVEL PHARMACEUTICALS LIMITED: SCENESSE approved for EPP in Canada | ||
| EDITAS MEDICINE | 2,580 | +2,79 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,102 | +2,04 % | CARDIOL THERAPEUTICS INC ruhig im strategischen Fokus | ||
| CELLECTAR BIOSCIENCES | 2,540 | -1,55 % | Cellectar publishes phase 1 data on multiple myeloma treatment | ||
| CYTODYN | 0,198 | 0,00 % | CytoDyn Inc.: CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer's Disease | Phase 2a study will evaluate the safety and biological activity of leronlimab in patients over the age of 50 with early-stage, biomarker-confirmed Alzheimer's disease VANCOUVER, Washington, June 11... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 0,789 | +3,68 % | CARDIFF ONCOLOGY INC im strukturellen Gleichgewicht | ||
| EMERGENT BIOSOLUTIONS | 6,670 | -0,74 % | Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine)] to Support U.S. Biodefense Strategy | GAITHERSBURG, Md., May 28, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has been awarded a contract modification valued at approximately $64.5 million from the... ► Artikel lesen | |
| DENALI THERAPEUTICS | 19,670 | -1,06 % | Will Recent Setbacks Impact Growth Prospects of DNLI Stock? | ||
| CEL-SCI | 1,000 | 0,00 % | CEL-SCI launches confirmatory study for head and neck cancer drug | ||
| CYTOKINETICS | 68,32 | -2,76 % | Wall Street Analysts Think Cytokinetics (CYTK) Could Surge 30.54%: Read This Before Placing a Bet | ||
| COHERUS ONCOLOGY | 1,220 | +1,41 % | Coherus Oncology, Inc.: Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI (toripalimab-tpzi) | REDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS) and Zumutor Biologics Inc. ("Zumutor"), an immuno-oncology biotech company, today announced a clinical... ► Artikel lesen | |
| CURIS | 4,220 | +7,38 % | XFRA CUS1: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 3,240 | +1,12 % | CytomX Therapeutics Inc.: CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer | - Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX's PROBODY- and Regeneron's Veloci-Bi- platforms - - CytomX to receive... ► Artikel lesen | |
| FATE THERAPEUTICS | 2,328 | -2,27 % | H.C. Wainwright reiterates Fate Therapeutics stock rating at buy |
Das Unternehmen CALIDI BIOTHERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,120 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CALIDI BIOTHERAPEUTICS INC finden Sie auf Wallstreet Online.